Task V02: Immunogenicity and Efficacy Testing of Medical Countermeasures (Vaccines and Other Biologics) against BSL-4 Pathogens in Non-Human Primates

任务 V02：针对非人类灵长类动物中 BSL-4 病原体的医疗对策（疫苗和其他生物制品）的免疫原性和功效测试

• 批准号: 10636609
• 负责人: THOMAS RUDGE
• 金额: $ 13.41万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10636609
• 关键词: Biological; Biological Products; Communicable Diseases; Contracts; Development; Ebola Vaccines; Feasibility Studies; Filovirus; Investigational New Drug Application; Licensing; Marburgvirus; Services; Vaccines; efficacy testing; evaluation/testing; immunogenicity; medical countermeasure; nonhuman primate; novel vaccines; pathogen; product development; testing services; vaccine candidate; vaccine development

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against a wide array of infectious diseases.

传染病合同的疫苗和其他生物制剂的评估和测试服务（ETS）提供了各种产品开发服务，从早期可行性研究到提交生物许可应用（BLA）和/或研究新药（IND）应用所需的活动。这些服务将促进和引入新的候选疫苗和生物制剂（由CBER调节），以针对各种各样的传染病。